...
机译:MA16.03全球RET注册表(荣耀):RET重新排列的肺癌中的RET定向靶向疗法的活动
Medical Oncology Lucerne Cantonal Hospital;
Oncologie Thoracique Hopital Larrey;
Institut Claudius Regaud Institut Universitaire Du Cancer Toulouse;
Oncology Cio;
Medical Oncology Ohio State University Comprehensive Cancer Center;
Ohio State University Comprehensive Cancer Center;
Medicine University of Colorado;
Medicine University of Colorado;
Division of Medical Oncology University of Colorado;
Department of Cancer Medicine;
Department of Medical Oncology;
Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute;
Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute;
Thoracic Cancer Unit Davidoff Cancer Center;
Yonsei Cancer Center;
University of Texas MD Anderson Cancer Center;
Netherlands Cancer Institute;
Department of Medicine Division of Oncology Stanford University;
Medicine (Oncology) Stanford Cancer Intitute/Stanford University;
Princess of Wales Hospital The Chinese University of Hong Kong;
Department of Oncology National Taiwan University Hospital;
University of California at Irvine;
Fachkliniken Wangen;
Eoc;
University Hospital Bichat;
University of California Davis Cancer Center;
University of California Davis Cancer Center;
Cleveland Clinic;
Medical Oncology Lucerne Cantonal Hospital;
Medical Oncology Lucerne Cantonal Hospital;
Kantonsspital St. Gallen;
Oncology Cio;
Centre Hospitalier Intercommunal de Creteil;
Royal Marsden Hospital;
Hospital Germans Trias I Pujol Catalan Institute of Oncology;
Instituto Oncológico Dr Rosell (IOR) Hospital Universitario Quirón-Dexeus;
Medical Oncology University Hospital Basel;
National Taiwan University Hospital;
Heidelberg University Hospital;
Translational Research Unit Thoraxklinik at University of Heidelberg and Translational Lung;
Université de Rennes 1;
University Hospital;
Memorial Sloan Kettering Cancer Center;
机译:MA16.03全球RET注册表(荣耀):RET重新排列的肺癌中的RET定向靶向疗法的活动
机译:靶向RET重新排列的肺癌患者:全球多中心RET登记处的结果
机译:RET重排非小细胞肺癌靶向治疗:临床发展及未来方向
机译:使用靶标质谱法的肺癌化疗基于等离子体的预测标志物优先化
机译:抑制Ape1的DNA修复活性作为癌症靶标:鉴定具有翻译潜力的新型小分子,可用于分子靶向癌症治疗
机译:以RET重排的肺癌患者为目标的RET:全球多中心RET注册中心的结果
机译:MA16.03全球RET注册表(荣耀):RET重新排列的肺癌中的RET定向靶向疗法的活动